ReviewNature reviews. Neuroscience2015
Auditory dysfunction in schizophrenia: integrating clinical and basic features.
Review in Nature reviews. Neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 209 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
209 citing papers in PubMed, 3 syntheses or guidelines pooled it, 378 citations in OpenAlex.
- Critical period plasticity-related transcriptional aberrations in schizophrenia and bipolar disorder.Schizophrenia research · 2019Pooled it
- Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia.Schizophrenia research · 2018Pooled it
- A Meta-analytic Review of Auditory Event-Related Potential Components as Endophenotypes for Schizophrenia: Perspectives From First-Degree Relatives.Schizophrenia bulletin · 2016Pooled it
- An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.Journal of psychopharmacology (Oxford, England) · 2023Trial
- Functional connectivity signatures of NMDAR dysfunction in schizophrenia-integrating findings from imaging genetics and pharmaco-fMRI.Translational psychiatry · 2023Trial
- Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Trial
- Durable Cognitive Gains and Symptom Improvement Are Observed in Individuals With Recent-Onset Schizophrenia 6 Months After a Randomized Trial of Auditory Training Completed Remotely.Schizophrenia bulletin · 2022Trial
- CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.Psychopharmacology · 2020Trial
- Transcranial direct current stimulation over the sensory-motor regions inhibits gamma synchrony.Human brain mapping · 2019Trial
- Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia.Schizophrenia research · 2019Trial
- Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care.Schizophrenia research · 2018Trial
- The effect of bilateral transcranial direct current stimulation on early auditory processing in schizophrenia: a preliminary study.Journal of neural transmission (Vienna, Austria : 1996) · 2017Trial
- Neurophysiological Effects of Bitopertin in Schizophrenia.Journal of clinical psychopharmacology · 2017Trial
- Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.Brain : a journal of neurology · 2016Trial
- Article
- Protocol for analyzing slow cortical dynamics in mouse neuronal recordings.STAR protocols · 2026Article
- Schizophrenia: temporal imprecision in phase, time, and frequency domains.Schizophrenia (Heidelberg, Germany) · 2026Article
- Glutamatergic Modulators in Schizophrenia: Are We Ready to Move Beyond the Narrow Focus on Dopamine? A Potential Paradigm Shift in Psychopharmacology.Alpha psychiatry · 2026Article
- Quantifying the Influence of Lexical Surprisal on Acoustic Speech Encoding While Controlling for Within-Speaker Variability.The European journal of neuroscience · 2026Article
- Schizophrenia disrupts normative covariation of neural activity across modalities of perception.Journal of psychopathology and clinical science · 2026Article
149 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Schizophrenia is a complex neuropsychiatric disorder that is associated with persistent psychosocial disability in affected individuals. Although studies of schizophrenia have traditionally focused on deficits in higher-order processes such as working memory and executive function, there is an increasing realization that, in this disorder, deficits can be found throughout the cortex and are manifest even at the level of early sensory processing. These deficits are highly amenable to translational investigation and represent potential novel targets for clinical intervention. Deficits, moreover, have been linked to specific structural abnormalities in post-mortem auditory cortex tissue from individuals with schizophrenia, providing unique insights into underlying pathophysiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.